RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCIE SCOPUS

      Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone

      한글로보기

      https://www.riss.kr/link?id=A103570372

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin’s lymphoma arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a detectable tumor. The effusion contains tumor cells un...

      Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin’s lymphoma arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a detectable tumor. The effusion contains tumor cells universally infected with human herpesvirus 8 (HHV8), which is the critical factor differentiating PEL from HHV8-unrelated PEL-like lymphoma (PEL-LL). This report describes a 77-year-old male patient with pleural effusion and ascites, containing lymphoma cells expressing a B-cell phenotype, but without markers of HHV8 in immunocytochemical analysis. The patient was diagnosed with PEL-LL and treated with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in a complete remission. The patient is currently disease-free 15 months post-treatment. To the best of our knowledge, this is the first report on administration of R-CHOP in a PEL-LL patient in South Korea.

      더보기

      참고문헌 (Reference)

      1 Toyoda K, "Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma" 55 : 815-819, 2014

      2 Castillo JJ, "Prognosis in primary effusion lymphoma is associated with the number of body cavities involved" 53 : 2378-2382, 2012

      3 Nador RG, "Primary effusion lymphoma : a distinct clinicopathologic entity associated with the Kaposi's sarcomaassociated herpes virus" 88 : 645-656, 1996

      4 Chen YB, "Primary effusion lymphoma" 12 : 569-576, 2007

      5 Carbone A, "PEL and HHV8-unrelated effusion lymphomas : classification and diagnosis" 114 : 225-227, 2008

      6 Wang HY, "Notch1 in primary effusion lymphoma : a clinicopathological study" 23 : 773-780, 2010

      7 Alexanian S, "KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states" 37 : 241-249, 2013

      8 Wu W, "Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma : report of a rare case and review of 54 cases in the literature" 140 : 258-273, 2013

      9 Fan HB, "Human herpes virus 8-unrelated primary effusion lymphomalike lymphoma in a patient with hepatitis B virus-related liver cirrhosis : a case report" 19 : 190-192, 2014

      10 Wu W, "Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma diagnosed by fluorodeoxyglucose positron emission tomography/computer tomography and laparoscopy" 7 : 433-434, 2014

      1 Toyoda K, "Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma" 55 : 815-819, 2014

      2 Castillo JJ, "Prognosis in primary effusion lymphoma is associated with the number of body cavities involved" 53 : 2378-2382, 2012

      3 Nador RG, "Primary effusion lymphoma : a distinct clinicopathologic entity associated with the Kaposi's sarcomaassociated herpes virus" 88 : 645-656, 1996

      4 Chen YB, "Primary effusion lymphoma" 12 : 569-576, 2007

      5 Carbone A, "PEL and HHV8-unrelated effusion lymphomas : classification and diagnosis" 114 : 225-227, 2008

      6 Wang HY, "Notch1 in primary effusion lymphoma : a clinicopathological study" 23 : 773-780, 2010

      7 Alexanian S, "KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states" 37 : 241-249, 2013

      8 Wu W, "Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma : report of a rare case and review of 54 cases in the literature" 140 : 258-273, 2013

      9 Fan HB, "Human herpes virus 8-unrelated primary effusion lymphomalike lymphoma in a patient with hepatitis B virus-related liver cirrhosis : a case report" 19 : 190-192, 2014

      10 Wu W, "Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma diagnosed by fluorodeoxyglucose positron emission tomography/computer tomography and laparoscopy" 7 : 433-434, 2014

      11 Kashiwagi T, "HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma with genotypic infidelity and c-MYC expression" 93 : 1609-1610, 2014

      12 Little RF, "HIV-associated non-Hodgkin lymphoma : incidence, presentation, and prognosis" 285 : 1880-1885, 2001

      13 Okada S, "Current status of treatment for primary effusion lymphoma" 3 : 65-74, 2014

      14 Mohammad F, "A unique case of malignant pleuropericardial effusion : HHV-8-unrelated PEL-like lymphoma : a case report and review of the literature" 2014 : 436821-, 2014

      15 Kyung Ho Kim, "A Case of Human Herpes Virus-8 Unrelated Primary Effusion Lymphoma-Like Lymphoma Presented as Pleural Effusion" 대한결핵및호흡기학회 73 (73): 336-341, 2012

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2024 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2021-01-01 평가 등재학술지 선정 (해외등재 학술지 평가) KCI등재
      2020-12-01 평가 등재후보로 하락 (해외등재 학술지 평가) KCI등재후보
      2010-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2008-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2005-05-27 학술지명변경 한글명 : 대한암학회지 -> Cancer Research and Treatment KCI등재
      2005-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2004-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2002-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 3.58 0.89 3.01
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      2.62 2.28 1.846 0.26
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼